High Lipoprotein(a) Levels As a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2020 Apr 21

PMID 32308405

Citations 3

Authors

I Dewa Gde Dwi Sumarjaya

I Ketut Badjra Nadha

Anak Agung Wiradewi Lestari

Affiliations

Soon will be listed here.

Abstract

Background: Risk stratification models with incorporation of biochemical markers have received attention recently. In acute myocardial infarction (AMI) one such marker is lipoprotein(a) (Lp(a)). Lp(a) has prothrombotic and proinflammatory properties. High levels of Lp(a) probably contribute to the additional adverse effects in AMI, as it enhances the damaging effect of acute thrombosis. This study aimed to evaluate serum Lp(a) as a predictor of major adverse cardiovascular events (MACE) in hospitalized-acute myocardial infarction patients.

Methods: A prospective cohort study was conducted at Sanglah Hospital, Denpasar, during June-August 2018, among 66 people by consecutive sampling. Samples that met the inclusion and exclusion criteria were examined for serum Lp(a) at the time of admission and the occurrence of MACE during hospitalization was observed. Data regarding serum Lp(a), demography, smoking history, dyslipidemia, hypertension, diabetes mellitus, and MACE were collected. Log rank test and Cox proportional hazards regression were conducted with SPSS version 20 for Windows.

Results: During observation, MACE occurred in 25 (38%) patients, including cardiogenic shock in 7 (10.6%) patients, heart failure in 20 (30.3%) patients, cardiovascular death in 5 (7, 6%) patients, malignant arrhythmias in 5 (7.6%) patients, and postinfarction angina in 5 (7.6%) patients. After the Log rank test, a significant difference in survival was observed (p = 0.001) between groups of high Lp(a) (survival rate of 60.6 hours; 95% CI 43.3-77.9) and low Lp(a) (average survival of 104.3 hours, 95% CI 91.4-117.2). The hazard ratio of high Lp(a) against MACE was 4.63 (p=0.002), and it increased to 4.69 in multivariate analysis with Cox proportional hazards regression test (p=0.003).

Conclusion: The high level of Lp(a) in AMI patients was a risk factor for the occurrence of MACE during hospitalization. Patients with high Lp(a) also had worse survival compared to patients with low Lp(a).

Citing Articles

Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure.

Zhang B, Xu Y, Huang X, Sun T, Ma M, Chen Z Front Cardiovasc Med. 2024; 11:1466146.

PMID: 39301496 PMC: 11410592. DOI: 10.3389/fcvm.2024.1466146.

Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.

Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J BMC Cardiovasc Disord. 2024; 24(1):395.

PMID: 39080549 PMC: 11287928. DOI: 10.1186/s12872-024-04057-w.

Hypertensive Disorders of Pregnancy: Assessing the Significance of Lp(a) and ApoB Concentrations in a Romanian Cohort.

Abu-Awwad S, Craina M, Boscu L, Bernad E, Ciordas P, Marian C J Pers Med. 2023; 13(9).

PMID: 37763183 PMC: 10532696. DOI: 10.3390/jpm13091416.

References

Schwartz G, Ballantyne C, Barter P, Kallend D, Leiter L, Leitersdorf E . Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2017; 3(2):164-168. PMC: 5838593. DOI: 10.1001/jamacardio.2017.3833. View

Fox K, Eagle K, Gore J, Steg P, Anderson F . The Global Registry of Acute Coronary Events, 1999 to 2009--GRACE. Heart. 2010; 96(14):1095-101. DOI: 10.1136/hrt.2009.190827. View

Tada H, Takamura M, Kawashiri M . Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019; 26(7):583-591. PMC: 6629747. DOI: 10.5551/jat.RV17034. View

Gomez M, Valle V, Aros F, Sanz G, Sala J, Fiol M . Oxidized LDL, lipoprotein (a) and other emergent risk factors in acute myocardial infarction (FORTIAM study). Rev Esp Cardiol. 2009; 62(4):373-82. DOI: 10.1016/s1885-5857(09)71664-0. View

Tsironis L, Mitsios J, Milionis H, Elisaf M, Tselepis A . Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004; 63(1):130-8. DOI: 10.1016/j.cardiores.2004.03.005. View

Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White I . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302(4):412-23. PMC: 3272390. DOI: 10.1001/jama.2009.1063. View

Wang Z, Zhai X, Xue M, Cheng W, Hu H . Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis. Lipids Health Dis. 2019; 18(1):150. PMC: 6615167. DOI: 10.1186/s12944-019-1092-6. View

Malaguarnera M, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L . Lipoprotein(a) in cardiovascular diseases. Biomed Res Int. 2013; 2013:650989. PMC: 3591100. DOI: 10.1155/2013/650989. View

Barre D . Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res. 2006; 119(5):601-7. DOI: 10.1016/j.thromres.2006.04.013. View

10.

Craig W, Neveux L, Palomaki G, Cleveland M, Haddow J . Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998; 44(11):2301-6. View

11.

Danesh J, Collins R, Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102(10):1082-5. DOI: 10.1161/01.cir.102.10.1082. View

12.

Cho J, Jeong M, Ahn Y, Hong Y, Park H, Yoon N . High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes. Korean Circ J. 2010; 40(10):491-8. PMC: 2978291. DOI: 10.4070/kcj.2010.40.10.491. View

13.

Waldeyer C, Makarova N, Zeller T, Schnabel R, Brunner F, Jorgensen T . Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017; 38(32):2490-2498. PMC: 5837491. DOI: 10.1093/eurheartj/ehx166. View

14.

Ikenaga H, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Miura F . Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J. 2011; 75(12):2847-52. DOI: 10.1253/circj.cj-11-0365. View

15.

Donataccio M, PiaDonataccio M, Puymirat E, Vassanelli C, Blanchard D, le Breton H . Presentation and revascularization patterns of patients admitted for acute coronary syndromes in France between 2004 and 2008 (from the National Observational Study of Diagnostic and Interventional Cardiac Catheterization [ONACI]). Am J Cardiol. 2013; 113(2):243-8. DOI: 10.1016/j.amjcard.2013.09.014. View

16.

Rand M, Sangrar W, Hancock M, Taylor D, Marcovina S, Packham M . Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998; 18(9):1393-9. DOI: 10.1161/01.atv.18.9.1393. View

17.

Nave A, Lange K, Leonards C, Siegerink B, Doehner W, Landmesser U . Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015; 242(2):496-503. DOI: 10.1016/j.atherosclerosis.2015.08.021. View

18.

Yan A, Yan R, Tan M, Casanova A, Labinaz M, Sridhar K . Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007; 28(9):1072-8. DOI: 10.1093/eurheartj/ehm004. View

19.

Kojima S, HARPEL P, Rifkin D . Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991; 113(6):1439-45. PMC: 2289027. DOI: 10.1083/jcb.113.6.1439. View

20.

Willeit P, Kiechl S, Kronenberg F, Witztum J, Santer P, Mayr M . Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014; 64(9):851-60. DOI: 10.1016/j.jacc.2014.03.061. View